Plazzi G, Dauvilliers Y, Mignot E, Sterkel A, Leary EB, Yong L, Accardi MA, Kanes S. ORX750, an Oral Orexin Receptor 2 Agonist, in Participants with Narcolepsy Type 1: Preliminary Results from a Phase 2a Trial Crossover Analysis. Sleep 49(suppl_1), In Press.

Plazzi G, Dauvilliers Y, Mignot E, Sterkel A, Salek Y, Kozauer S, Leary EB, Yong L, Accardi MA, Kanes S. ORX750, an Oral Orexin Receptor 2 Agonist, in Participants with Narcolepsy Type 1: Preliminary Results from a Phase 2a Trial Parallel-Design Analysis. Sleep 49(suppl_1), In Press.

Joshi R, Luu C, Dickstein E, Leary EB, Mignot E, Kushida C, Cederberg K. Sleep disorder complaints and risks in adults with ADHD. Sleep 49(suppl_1), In Press.

Solriamfetol significantly improved sleepiness compared with placebo in early-morning shift workers with Shift Work Disorder.

We evaluated the efficacy of solriamfetol for treating excessive sleepiness in early-morning shift workers with shift work disorder. In this randomized, placebo-controlled trial of 78 participants, solriamfetol significantly improved wakefulness on the maintenance of wakefulness test (9.4-minute increase in sleep latency, 95% confidence interval [CI], 5.7 to 13.0; P<0.001) and reduced subjective sleepiness with consistent improvements across clinician- and patient-reported measures.

Zitting KM, Gilmore KR, Lockyer BJ, Leary EB, Wang W, Issa NC, Quan SF, Williams JS, Duffy JF, Czeisler CA. Solriamfetol for Excessive Sleepiness in Early-Morning Shift Work Disorder. NEJM Evid. 2026 Feb;5(2):EVIDoa2500190. doi: 10.1056/EVIDoa2500190. Epub 2026 Jan 27. PMID: 41590992.

Plazzi G, Dauvilliers Y, Plante D, Mignot E, Roth T, Sterkel A, Leary EB, Hartman D, Accardi MA, Saha S, Kanes S. Development of a Novel, Oral Orexin Receptor 2 Agonist, ORX750 for Treatment of Patients with Narcolepsy (type 1 and 2) and Idiopathic Hypersomnia. Sleep Medicine Suppl 1, Abstracts from the 18th World Sleep Congress, Sept 2025.

Leary EB, Van Dongen HPA, Drake C, Bogan R, Jaeger J, Streicher C, Tabuteau H. Daily solriamfetol improved difficulty with memory and thinking in people with obstructive sleep apnea and excessive daytime sleepiness experiencing such difficulty: a plain language summary. Postgrad Med. 2025 Apr-May;137(3-4):209-219. DOI: 10.1080/00325481.2025.2494499. Epub 2025 May 5. PMID: 40325548.

Zitting KM, Gilmore KR, Lockyer BJ, Leary EB, Quan SF, Wang W, Issa N, Williams JS, Duffy JF, Czeisler CA. Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Early Morning Shift Work Disorder. Sleep 48(suppl_1), May 2025, Page A383, https://doi.org/10.1093/sleep/zsaf090.0881.

Thorpy MJ, Krahn LE, Bogan RK, Corser BC, Shapiro C, Chen D, Chhabra A, Leary EB, Tabuteau H. Impact of AXS-12 on Symptom Severity and Functional Impairment in Narcolepsy: Results from the Phase 3 SYMPHONY Trial. Sleep 48(suppl_1), May 2025, Page A359, https://doi.org/10.1093/sleep/zsaf090.0828.

Bogan RK, Thorpy MJ, Krahn LE, Corser BC, Shapiro C, Chen D, Chhabra A, Leary EB, Tabuteau H. ENCORE: Topline Results of a Phase 3 Open-Label Extension and Randomized Withdrawal Trial of AXS-12 in Narcolepsy. Sleep 48(suppl_1), May 2025, Page A365-A366, https://doi.org/10.1093/sleep/zsaf090.0843.

Thorpy MJ, Kant A, Harper K, Leary EB, Eglit G, Floam S, Tabuteau H. Residual Symptom burden in Patients With Narcolepsy Satisfied With Treatment: Subgroup Analysis From The CRESCENDO Survey. Sleep 48(suppl_1), May 2025, Page A359, https://doi.org/10.1093/sleep/zsaf090.0829.

Dias B, Mejia G, Lomba S, Lemer A, Keenan S, Mah C, Leary EB, Mignot E, Pelayo R. Longitudinal Effects of Sleep Education on Undergraduates and Graduates Students: Insights from Stanford University's Dement's Sleep and Dreams. Sleep 48(suppl_1), Page A588, https://doi.org/10.1093/sleep/zsaf090.1367.

Husain AM, Zee PC, Leary EB, Fuller DS, Candler S, Whalen M, Gow M, Bae CJ. Experiences of People With Narcolepsy Who Switched From Sodium Oxybate to Low-Sodium Oxybate: A Plain Language Summary. Future Neurology, 20:1, 2488245, DOI: 10.1080/14796708.2025.2488245.

Invited Panel Member
Participated in doctoral student professional development seminar on non-academic career paths

Flygare J, Oglesby L, Parthasarathy S, Thorpy MJ, Mignot E, Leary EB, Morse AM. Social support and isolation in narcolepsy and idiopathic hypersomnia: An international survey. Sleep Med. 2025 Jan;125:65-73. DOI: 10.1016/j.sleep.2024.11.013. Epub 2024 Nov 12. PMID: 39561673.

Results of the Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-Controlled Study (SHARP)

We evaluated solriamfetol’s effect on cognitive function in patients with obstructive sleep apnea and excessive daytime sleepiness. In this randomized crossover trial of 59 participants, solriamfetol significantly improved cognitive performance (DSST; effect size 0.37) compared to placebo, with consistent improvements in subjective cognition, sleepiness, and global severity.

Leary EB*, Van Dongen HPA*, Drake C, Bogan R, Jaeger J, Rosenberg R, Streicher C, Tabuteau H. Results of the Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-Controlled Study (SHARP): A Randomized Placebo-Controlled Double-Blind Repeated-Measures Crossover Phase IV Clinical Trial of the Effect of the Wake-Promoting Agent Solriamfetol on Cognitive Function in OSA With Excessive Daytime Sleepiness and Cognitive Impairment. Chest. 2024 Nov 9: S0012-3692(24)05470-9. DOI: 10.1016/j.chest.2024.10.050. Epub ahead of print. PMID: 39528111. (* equal contribution)